Bildkälla: Stockfoto

Cyxone: Our Q1 Comment - Redeye

Redeye comments on Cyxone’s Q1 report and potential impact on the new strategy. We also adjust our base case to reflect our assumption that the company needs additional funding to finalize the phase IIb trial with Rabeximod.

Redeye comments on Cyxone’s Q1 report and potential impact on the new strategy. We also adjust our base case to reflect our assumption that the company needs additional funding to finalize the phase IIb trial with Rabeximod.
Börsvärldens nyhetsbrev
ANNONSER